Altimmune with ticker code (ALT) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 30 and 12 and has a mean target at 24.29. With the stocks previous close at 13.77 this indicates there is a potential upside of 76.4%. The day 50 moving average is 10.85 and the 200 moving average now moves to 8.36. The market capitalisation for the company is $843m. Find out more information at: https://altimmune.com
The potential market cap would be $1,486m based on the market concensus.
Altimmune, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune in September 2015. Altimmune was founded in 1997 is headquartered in Gaithersburg, Maryland.
